What is Compugen?
Compugen operates at the forefront of therapeutic discovery and development, leveraging its proprietary computational discovery platforms. These advanced systems are designed to identify novel drug targets and subsequently develop therapeutics, with a primary focus on the field of cancer immunotherapy. The company's approach aims to streamline the drug discovery process by utilizing predictive computational methods to pinpoint promising therapeutic avenues. This strategic utilization of technology allows Compugen to build a robust pipeline of potential treatments for complex diseases.
How much funding has Compugen raised?
Compugen has raised a total of $71M across 2 funding rounds:
Stock Offering
$51M
Stock Offering
$20M
Stock Issuance/Offering (2014): $51M, investors not publicly disclosed
Stock Issuance/Offering (2021): $20M led by Bristol-Myers Squibb
Key Investors in Compugen
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and manufacturing prescription medications for serious patient needs in areas like oncology, cardiovascular disease, and immunoscience. They invest heavily in R&D and pursue collaborative approaches to medical innovation.
What's next for Compugen?
With the recent influx of major strategic investment, Compugen is poised for accelerated growth and development. The company is expected to further invest in its research and development initiatives, focusing on advancing its pipeline of cancer immunotherapies and other novel therapeutics. This capital infusion will likely support expanded clinical trials, further platform enhancements, and potential strategic partnerships. The company's trajectory suggests a continued focus on translating its computational discovery capabilities into tangible therapeutic solutions for unmet medical needs.
See full Compugen company page
